Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Recombinant Interferon Beta | |
| Synonyms |
|
|
| Definitions |
A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C495 |
|
| Accepted_Therapeutic_Use_For |
multiple sclerosis
|
|
| CAS_Registry |
77238-31-4
|
|
| code |
C495
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)
|
|
| Display_Name |
Recombinant Interferon Beta
|
|
| FDA_UNII_Code |
V9GU1EM8SF
|
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Related_To_Endogenous_Product | ||
| Is_Value_For_GDC_Property | ||
| label |
Recombinant Interferon Beta
|
|
| Legacy Concept Name |
Therapeutic_Interferon_Beta
|
|
| Maps_To |
Recombinant Interferon Beta
|
|
| NCI_Drug_Dictionary_ID |
40468
|
|
| NSC Number |
373361 658933
|
|
| PDQ_Closed_Trial_Search_ID |
40468
|
|
| PDQ_Open_Trial_Search_ID |
40468
|
|
| Preferred_Name |
Recombinant Interferon Beta
|
|
| prefixIRI |
NCIT:C495
|
|
| prefLabel |
Recombinant Interferon Beta
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C0015980
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
| Mapping To | Ontology | Source |
|---|---|---|
| http://purl.bioontology.org/ontology/PDQ/CDR0000040468 | PDQ | LOOM |
| http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C495 | NCIT | LOOM |